Johnson & Johnson to Pay Over $81 Million in Topamax Drug Case

WASHINGTON (Reuters) - Two Johnson and Johnson subsidiaries agreed to pay more than $81 million to resolve allegations of illegal promotion of the epilepsy drug Topamax, the U.S. Justice Department said on Thursday.